BIOHOPE SCIENTIFIC SOLUTIONS FOR HUMAN HEALTH SL

Their core work

BIOHOPE is a Spanish biotech SME based in Tres Cantos (Madrid) developing diagnostic assays for kidney transplant patients. Their core product is a cellular biotechnology test that helps clinicians predict and monitor how a transplanted kidney will respond to immunosuppressive drugs — so dosing can be personalized instead of standardized. This addresses a real clinical gap: rejection and over-immunosuppression are leading causes of graft loss, and there are few tools to stratify patients before complications appear. They moved the product from feasibility study through to clinical and commercial development under the EU SME Instrument.

What they specialise in

How they've shifted over time

Between the 2015 feasibility phase and the 2017 full-development phase, BIOHOPE shifted their language from 'biomarker-based assay' to 'cellular biotechnology' — suggesting they moved from a biomarker signature approach to a live-cell functional test as the commercial product. The clinical target (prognosis and monitoring in renal transplantation) stayed constant, but the underlying technology matured. After 2019 there is no visible H2020 follow-up activity in the data, so their current trajectory post-SME-2 cannot be confirmed from EU project records alone.

They completed a full SME-Instrument pipeline by 2019 and are likely in clinical deployment or market-entry mode for their transplant-monitoring product — a partner to approach for commercial distribution, clinical studies, or IVDR regulatory work rather than early-stage research.

How they like to work

BIOHOPE has coordinated both of their H2020 projects as a solo SME-Instrument beneficiary, which is the standard structure for Phase 1 and most Phase 2 SME grants. This means they act as a self-contained technology developer rather than a consortium hub, and their H2020 footprint shows no formal consortium partners. Anyone working with them should expect a small, focused commercial team rather than an academic network.

No H2020 consortium partners are recorded because both their projects were single-beneficiary SME-Instrument grants. Geographic reach within EU research funding is therefore limited to their own Spanish base.

What sets them apart

BIOHOPE is one of the few European SMEs that took a kidney-transplant monitoring diagnostic all the way from EU feasibility grant (SME-1) to a €3.85M SME-2 development grant — a signal that EU reviewers validated both their science and their commercial plan. They occupy a narrow clinical niche (transplantation nephrology diagnostics) where specialist IVD players are rare. Partnering with them makes sense for transplant centers wanting access to a validated monitoring tool, or for diagnostic distributors looking for differentiated nephrology products.

Highlights from their portfolio

• TRANSBIO (2015-2016)
  The €50k SME-1 feasibility phase that de-risked the concept and unlocked the Phase 2 funding — a textbook SME-Instrument progression.
• TRANSBIO (2017-2019)
  Their flagship €3.85M SME-2 grant that took the renal-transplant diagnostic from feasibility to clinical and commercial development.